TrovaGene (TROV) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of TrovaGene (NASDAQ:TROV) from a sell rating to a hold rating in a research note released on Tuesday.

According to Zacks, “Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics’ patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. “

Several other analysts have also recently weighed in on TROV. ValuEngine raised TrovaGene from a sell rating to a hold rating in a report on Saturday, June 2nd. HC Wainwright set a $7.00 price target on TrovaGene and gave the stock a buy rating in a report on Monday, June 4th. Finally, Maxim Group raised TrovaGene from a hold rating to a buy rating in a report on Friday, June 15th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. TrovaGene currently has a consensus rating of Hold and an average price target of $19.17.

NASDAQ:TROV opened at $0.79 on Tuesday. The company has a market cap of $14.06 million, a P/E ratio of -0.12 and a beta of -0.14. TrovaGene has a 1-year low of $0.65 and a 1-year high of $12.96.

TrovaGene (NASDAQ:TROV) last released its quarterly earnings results on Friday, August 3rd. The medical research company reported ($0.44) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.11). The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.10 million. TrovaGene had a negative return on equity of 188.93% and a negative net margin of 2,970.66%. analysts predict that TrovaGene will post -1.28 earnings per share for the current year.

In other news, Director Rodney S. Markin purchased 41,200 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The stock was acquired at an average cost of $0.85 per share, with a total value of $35,020.00. Following the acquisition, the director now owns 63,810 shares in the company, valued at approximately $54,238.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.30% of the company’s stock.

A hedge fund recently raised its stake in TrovaGene stock. Renaissance Technologies LLC boosted its stake in shares of TrovaGene Inc (NASDAQ:TROV) by 58.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 203,802 shares of the medical research company’s stock after acquiring an additional 75,131 shares during the period. Renaissance Technologies LLC owned 1.15% of TrovaGene worth $157,000 at the end of the most recent reporting period. 9.02% of the stock is owned by institutional investors and hedge funds.

About TrovaGene

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

See Also: Penny Stocks, What You Need To Know

Get a free copy of the Zacks research report on TrovaGene (TROV)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit